Use of integrated imaging and serum biomarker profiles to identify subclinical dysfunction in pediatric cancer patients treated with anthracyclines

Table 3 Multilevel linear regression (biomarkers to changes in LV Ejection Fraction from V1 to V6)

	Coef.	SE	DF	t	p
εcc (%)	−1.5540	0.3924	35	−3.9605	<.001
ESV (ml)	−0.2496	0.0446	43	−5.5980	<.001
ESFS (g/cm²)	−0.1584	0.0451	43	−3.5114	.0011
MMP7 (pg/ml)	−0.0014	0.0006	43	−2.4592	.018
sIL 4R (pg/ml)	0.0034	0.0014	44	2.4405	.0188
sRage (pg/ml)	−0.0502	0.0216	44	−2.3234	.0248
sTNFRI (pg/ml)	−0.0032	0.0015	44	−2.1340	.0385
sTNFRII (pg/ml)	−0.0008	0.0003	44	−2.4872	.0167
sVEGFR3 (pg/ml)	−0.0058	0.0022	44	−2.6162	.0121

V1: first visit; V6: 1 year after maximal anthracycline therapy; εcc: Peak global longitudinal strain magnitude; ESV: End systolic volume; ESFS: End systolic fiber stress; MMP: Metalloproteinase; sILR: soluble interleukin receptor; sRage: receptor for advanced glycation end products; sTNFR: soluble receptor for TNF; sVEGFR: receptors for vascular endothelial growth factor

ISSN: 2057-3804